[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The University of Hong Kong\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":696},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,266,0,25,[9,52,79,106,130,156,183,208,235,259,287,316,343,368,395,419,451,472,506,533,561,591,616,637,663],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100646079","efficacy-of-cbt-i-with-adjuvant-melatonin-in-older-adults-chronic-insomnia-100646079",false,"NCT07695246","Efficacy of CBT-I With Adjuvant Melatonin in Older Adults Chronic Insomnia","Efficacy of Cognitive Behavioural Therapy for Insomnia With Adjuvant Melatonin Treatment in Older Adults With Chronic Insomnia: A Randomised Controlled Trial","SOAM","Inclusion Criteria:\n\n1. Chinese aged ≥ 60.\n2. Provision of written informed consent.\n3. Having a DSM-5 diagnosis of insomnia disorder (i.e., having difficulty initiating sleep, maintaining sleep, or early morning awakening at least three times a week for at least three months, with clinically significant impairment or distress).\n4. Having a score of \\> 14 on the ISI, indicating clinical insomnia.\n\nExclusion Criteria:\n\n1. Having a current diagnosis or a history of manic or hypomanic episodes, schizophrenia spectrum disorders, neurodevelopmental disorders, neurocognitive disorders, organic mental disorders, intellectual disabilities, or substance abuse or dependence.\n2. Having a progressive medical condition directly related to the onset and course of insomnia (e.g., cancer, chronic pain).\n3. Undergoing treatment for diseases known to affect sleep (e.g., chemotherapy).\n4. Having an untreated sleep disorder that may disrupt sleep continuity and quality (e.g., sleep-disordered breathing) except for insomnia disorder.\n5. Having mild to significant cognitive impairment, defined by having a score of \\\u003C 22 on MOCA.\n6. Concurrent and regular use of extraneous melatonin or melatonin agonist (e.g., ramelteon).\n7. Receiving concurrent psychological treatment for insomnia.\n8. Meeting potential contraindications for melatonin (e.g., undergoing dialysis) or concurrently using medications that have a potential drug interaction with melatonin (e.g., anticoagulant and anti-platelet).\n9. Being a night shift worker.","ALL","60 Years",{"count":21,"type":22},183,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study tests the efficacy of cognitive behavioural therapy for insomnia (CBT-I) with or without adjunct melatonin in older adults with insomnia. Adults aged 60 or above with chronic insomnia will be randomly assigned to one of three groups: (1) CBT-I plus nightly melatonin, (2) CBT-I plus nightly placebo tablet, or (3) sleep health psychoeducation plus nightly placebo tablet. All group sessions occur weekly for four weeks.",[28,29,30],"Insomnia","Aging","Sleep Disorders",[28,32,33,34,35,36,37,38],"Elderly","CBT","Melatonin","Circadian Rhythm","Sleep","Randomised controlled trial","Older adults","RECRUITING","2026-08-20",{"date":42,"type":43},"2026-08-21","ACTUAL",{"date":45,"type":43},"2026-08-01",{"date":47,"type":22},"2029-08-01",{"name":49,"class":50},"The University of Hong Kong","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":51},"100652687","new-robotic-knee-surgery-does-implant-type-affect-alignment-accuracy-100652687","NCT07777757","New Robotic Knee Surgery: Does Implant Type Affect Alignment Accuracy?","Comparison of Postoperative Knee Alignment to Planned Alignment Using Two Implant Types and a Novel Robotic Platform in Total Knee Replacement - A Randomized Controlled Trial","CAPTAIN","Inclusion Criteria:\n\n* Adults aged 18 years and older.\n* Diagnosis of symptomatic knee osteoarthritis requiring total knee replacement.\n* Ability to give informed consent.\n* Feasibility of using the two types of implants\n\nExclusion Criteria:\n\n\\- Severe radiographic knee OA (Kellgren-Lawrence grade 4) or severe knee pain (VAS\\>80mm\u002F100 mm) that could not tolerate further conservative management","18 Years",{"count":62,"type":22},100,[25],"Total knee replacement is a common surgery for patients with severe knee arthritis. To improve surgical accuracy, surgeons now use robotic systems to help plan and perform the procedure. A new robotic system called KUNWU® has been developed in Hong Kong. Unlike many other systems, it allows surgeons to choose from different brands of knee implants.\n\nThis study is a randomized controlled trial. It will compare two different types of knee implants (Attune and Persona) used together with the KUNWU® robotic system. The main goal is to see how accurately the robotic system helps achieve the knee alignment that was planned before surgery. Alignment refers to the straightness and balance of the knee joint after the implant is placed.\n\nParticipants will be adults with knee osteoarthritis who need a total knee replacement. They will be randomly assigned to receive either the Attune or Persona implant. All surgeries will be performed using the KUNWU® robotic system. Participants will have CT scans before and after surgery, and X-rays will be taken at regular follow-up visits over 24 months. Clinical assessments, including pain and function scores, will also be collected at various time points.\n\nThe study will take place at the Department of Orthopaedics \\& Traumatology, The Duchess of Kent Children's Hospital (DKCH). A total of 100 participants will be recruited. The study will run for approximately 36 months, with recruitment lasting 12 months and follow-up continuing for 24 months.\n\nThe results will help determine whether the new robotic system can consistently achieve the planned alignment regardless of which implant is used. This information may help surgeons make better decisions about implant selection and robotic surgery in the future.",[66],"Knee Osteoarthristis",[68,69,70,71],"Total Knee Replacement","Robotic-Assisted Surgery","Knee Alignment","Knee Osteoarthritis","2026-08-19",{"date":42,"type":43},{"date":75,"type":43},"2026-03-18",{"date":77,"type":22},"2028-12-31",{"name":49,"class":50},{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":51},"100652942","acupressure-as-long-term-intervention-to-slow-the-progression-of-earlymild-alzheimers-disease-100652942","NCT07779863","Acupressure as Long-term Intervention to Slow the Progression of Early\u002FMild Alzheimer's Disease","Caregiver-administered Acupressure as Long-term Intervention to Slow the Progression of Early\u002FMild Alzheimer's Disease With Blood Amyloid and Tau Biomarkers: a Randomized Controlled Trial","Inclusion Criteria:\n\n* have at least one of the following abnormal plasma amyloid and tau levels: Aβ42\u002FAβ40 ratio ≤ 0.17, p-tau217 \\> 0.15 pg\u002Fml, or\u002Fand p-tau181 \\> 3.3 pg\u002Fml\n* have mild neurocognitive disorder with the Montreal Cognitive Assessment, Hong Kong version (HK-MoCA) in classifying mild neurocognitive disorder, in which mild neurocognitive disorder is defined as those whose HK-MoCA score falls between the 16th and 2nd percentile of his\u002Fher peers adjusted for age and education\n\nExclusion Criteria:\n\n* show moderate-to-severe dementia, as evidenced by a HK-MoCA score falling below the 2nd percentile of his\u002Fher peers adjusted for age and education\n* cannot proficiently communicate due to language function impairment\n* have severe skin lesions on acupressure areas\n* had a surgery on the head or neck\n* have a medical condition that is a contraindication for acupressure.","85 Years",{"count":88,"type":22},188,[25],"This is an assessor-blinded, randomized controlled trial. A total of 188 older adults aged 60-85 years with early\u002Fmild AD will be recruited from care and attention homes for the elderly and elderly activity centres. They will be randomly assigned to receive least acupressure control (LAC) (n = 94) and CAE (n = 94), administered by caregivers (i.e., trained research assistants), for 3 sessions a week for 12 months. The primary outcome is the change in the MoCA score from baseline. The secondary outcomes include functional independence, psychological well-being, sleep quality, and health-related quality of life. The outcomes will be assessed at baseline and once bimonthly thereafter, totalling 7 sessions. A linear mixed-effect model will be applied to compare the primary and secondary outcomes. Three blood samples will be collected at baseline, 6 months, and 12 months, respectively, and the baseline blood sample will be immediately measured for the measurement of plasma Aβ42, Aβ40, p-tau181, and p-tau217, GFAP, and NfL. Repeated two-way variance (ANOVA) will be used to detect significant differences in blood biomarkers between the two groups. Linear regression will be conducted to examine inter-correlations between clinical outcomes and biomarker levels. Health and social care resource use will additionally be recorded at baseline, 6 months, and 12 months for the economic evaluation to examine the cost-effectiveness of the CAE intervention compared with LAC.",[92],"Alzheimer's Disease",[94,95,96,97],"Alzheimer's disease","Acupressure","Dementia","Amyloid and tau biomarkers","NOT_YET_RECRUITING","2026-08-18",{"date":42,"type":43},{"date":102,"type":22},"2027-01-01",{"date":104,"type":22},"2030-08-31",{"name":49,"class":50},{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":18,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":127,"leadSponsor":129,"locationsCount":51},"100565151","clinical-trial-for-acupuncture-in-adolescents-with-psychological-distress-and-insomnia-100565151","NCT06638450","Clinical Trial for Acupuncture in Adolescents With Psychological Distress and Insomnia","Dense Cranial Electroacupuncture Stimulation Plus Body Acupuncture for Adolescents With Psychological Distress: a Randomized Controlled Trial With Observations on Salivary Oxytocin and Cortisol Changes","Inclusion Criteria:\n\nParticipants will be eligible for this study if they:\n\n1. are experiencing anxiety as evidenced by a BAI-C score of at least 8 (no symptoms = 0-7; mild = 8-15; moderate = 16-25; severe = 26-63), and\u002For a C-BDI-II score of at least 14 (no symptoms = 0-13, mild = 14-19; moderate = 20-28; severe = 29-63);\n2. have symptoms that have persistent for more than 3 months;\n3. are able to provide informed consent for participation, and complete treatments and questionnaires as scheduled; and\n4. have no suicidal ideation, as evidenced by \"no\" answers or a score of \\\u003C3 for all questionnaires of the Columbia-Suicide Severity Rating Scale (C-SSRS).\n\nExclusion Criteria:\n\nParticipants will be excluded if they:\n\n1. have unstable systemic medical conditions that may limit their participation in the study, for example, severe liver, cardiovascular, or kidney impairment; gastrointestinal or endocrine dysfunction; malignancy; autoimmune disease; acute infectious disease; or any conditions with unstable vital signs or require intensive hospitalization;\n2. have bipolar or psychotic disorder (e.g. schizophrenia);\n3. have a history of brain injury or surgery;\n4. have alcohol abuse or substance abuse;\n5. are pregnant or in lactation, or intend to conceive;\n6. have heart pacemaker or other metal devices implanted in the body;\n7. have concurrent or use of drug treatment for anxiety\u002Fdepression in the previous 6 months;\n8. have treatment with acupuncture or brain stimulation in the previous 6 months;\n9. have a history of epilepsy;\n10. have a condition of bleeding tendency, or coagulopathy, or currently receiving anti-coagulant treatment; or\n11. involved in other interventional clinical studies in the last 3 months or any relevant condition potentially interfering with study evaluation.","15 Years","22 Years",{"count":116,"type":22},148,[25],"This is an assessor-blinded, randomized, MAS-controlled trial. A total of 148 adolescents aged 15-22 years experiencing mild to moderate anxiety or depressive symptoms will be recruited. They will be randomly assigned to DCEAS+BA (n = 74) and MAS (n = 74) for 2 sessions per week for 8 weeks, followed by a 4-week post-treatment observation period. A post-intervention visit will be held at week 12. The primary outcome will be assessed using the Chinese version of the Beck Anxiety Inventory (BAI-C). The secondary outcomes include the Beck Depression Inventory II (C-BDI-II) for depression, the Zung Self-Rating Anxiety Scale (SAS) and the Zung Self-Rating Depression Scale (SDS) as additional assessments for anxiety and depression, the Pittsburgh Sleep Quality Index (PSQI) for sleep quality, and the World Health Organization Quality of Life-Brief (WHOQOL-BREF) (HK version) for the general quality of life. Assessment will be carried out every 4 weeks till week 12, while saliva will be collected at baseline and at the end of the 8 weeks. Salivary oxytocin and cortisol will be analyzed. A generalized linear mixed-effect model will be applied to compare treatment outcomes over time in the two groups and linear regression will be conducted to examine intercorrelations among clinical improvement and changes in biomarker levels. Subgroup analysis will be conducted to identify specific effects of DCEAS+BA.",[120,28],"Psychological Distress",[122,28,123,124],"Psychological distress","Acupuncture","Adolescent",{"date":40,"type":43},{"date":99,"type":43},{"date":128,"type":22},"2028-09",{"name":49,"class":50},{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":138,"minAge":60,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":51},"100649381","effectiveness-of-a-mindfulness-centered-stress-management-ai-chatbot-to-reduce-stress-and-enhance-mental-health-among-men-who-have-sex-with-men-in-china-100649381","NCT07732621","Effectiveness of A Mindfulness-centered Stress Management AI Chatbot to Reduce Stress and Enhance Mental Health Among Men Who Have Sex With Men in China","Effectiveness of A Mindfulness-centered Stress Management AI Chatbot to Reduce Stress and Enhance Mental Health Among Men Who Have Sex With Men in China: A Randomized Controlled Trial Study","MSM","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Chinese\n3. Self-identify as MSM.\n4. Own a smartphone to ensure compatibility with the intervention platform.\n5. Mild to moderate perceived stress, defined as Chinese Perceived Stress Scale (PSS-14) score \\\u003C 43.\n\nExclusion Criteria:\n\n1. Diagnosed with an acute severe mental disorder, such as psychosis, major depressive disorder, or anxiety disorder;\n2. Currently receiving psychotherapy at enrollment.\n3. Report moderately severe to severe depressive symptoms, defined as a PHQ-9 total score greater than 14.\n4. Unable to provide online informed consent or complete study procedures.","MALE",{"count":140,"type":22},76,[25],"The goal of this randomized controlled trial is to evaluate the effectiveness of a mindfulness-centered stress management AI chatbot in reducing perceived stress and enhancing mental health among Chinese men who have sex with men (MSM).\n\nThe main questions it aims to answer are:\n\n1. Does the AI chatbot show a greater reduction in perceived stress compared to standardized psychoeducational materials?\n2. Does the AI chatbot improve mental health outcomes, including depressive and anxiety symptoms, subjective well-being, and emotion regulation?\n\nResearchers will compare the AI chatbot to a control group receiving psychoeducational materials to see if the chatbot works to reduce stress and improve mental health.\n\nParticipants will:\n\n1. Be randomized to use the AI chatbot (recommended at least 2 sessions per week, 10-15 minutes per session) or read psychoeducational materials (2 times per week) for 4 weeks.\n2. Complete online self-report questionnaires at baseline, post-intervention (Week 4), and 4-week follow-up.",[144],"Stress (Psychology)",[146,147,148],"stress","sexual minority","mindfulness","2026-08-17",{"date":72,"type":43},{"date":152,"type":22},"2026-07-31",{"date":154,"type":22},"2027-03-31",{"name":49,"class":50},{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":18,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":51},"100597984","early-phase-1-anti-diabetic-drug-exercise-and-healthy-diet-for-knee-osteoarthritis-with-overweightobesity-100597984","NCT07065591","Anti-Diabetic Drug, Exercise and Healthy Diet for Knee Osteoarthritis With Overweight\u002FObesity","Anti-Diabetic Drug, Exercise and Healthy Diet for Knee Osteoarthritis With Overweight\u002FObesity, a Randomized Controlled Trial","ADDED","Inclusion Criteria:\n\n* Men and women age between 40 and 80 years old, with overweight or obesity (body mass index ≥23 kg\u002Fm2) according to Hong Kong Centre for Health Protection definition of overweight and obesity.\n* Knee pain for 6+ months with Visual Analogue Scale (VAS) \\> 40mm\u002F100mm and\n* Meet the American College of Rheumatology criteria for knee OA\n* OA referred for consideration for joint replacement\n\nExclusion Criteria:\n\n* Severe radiographic knee OA (Kellgren-Lawrence grade 4) or severe knee pain (VAS\\>80mm\u002F100 mm) that could not tolerate further conservative management;\n* inflammatory arthritis like rheumatoid arthritis, crystal arthritis, etc.\n* Preexisting diabetes on antidiabetic drug or drug allergy to metformin.\n* Recent knee surgery of the same knee\n* Significant bone loss.\n* Concomitant neuromuscular diseases affecting lower limb function.\n* renal or liver impairment precluding use of metformin.\n* VitaminB12 deficiency","40 Years","80 Years",{"count":62,"type":22},[168],"EARLY_PHASE1","Obesity is associated with increased pain with knee osteoarthritis and increase progression of knee osteoarthritis while weight loss intervention has been shown to reduce pain and requirement of total knee replacement. In this study, the investigators will assess using diet modification with exercise, and metformin, a common, safe, diabetes mellitus medication that has been in use for 70 years to achieve better weight control to reduce knee pain. This helps the investigators to understand whether the combined treatment can reduce joint pain, reduce body weight and improve symptoms and requirement of total knee replacement.",[171],"Osteoarthritis (OA) of the Knee",[173,174,175],"knee osteoarthritis","diet modification","exercise therapy","2026-08-14",{"date":99,"type":43},{"date":179,"type":22},"2026-08-30",{"date":181,"type":22},"2028-07-17",{"name":49,"class":50},{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":18,"minAge":190,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":23,"phases":194,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":51},"100652021","efficacy-of-cognitive-behavioural-therapy-for-insomnia-and-bright-light-therapy-in-adolescents-with-adhd-insomnia-and-evening-chronotype-100652021","NCT07767617","Efficacy of Cognitive Behavioural Therapy for Insomnia and Bright Light Therapy in Adolescents With ADHD, Insomnia, and Evening Chronotype","Efficacy of Cognitive Behavioural Therapy for Insomnia and Bright Light Therapy in Adolescents With ADHD and Comorbid Insomnia and Evening Chronotype: A Randomised, Assessor Blind, Parallel-group Trial","Inclusion criteria:\n\nAn adolescent who meets the following criteria will be eligible for taking part in this study:\n\n1. aged 10-24 years old;\n2. ADHD diagnosis confirmed by DISC-IV;\n3. DSM-5 diagnosis of insomnia disorder with an ≥ 9 (suggested cut-off for adolescents);\n4. Being classified as evening chronotype according to the score on the Horne-Östberg Morning-Eveningness Questionnaire (MEQ) and having a sleep onset time of 11:15pm or later for 12 year olds, 11:30pm or later for 13-14 year olds, 12:00am or later for 15-17 years old \\[64\\], 10:56pm or later for 18-24 years old at least 3 nights per week in the past 3 months and as confirmed by a 7-day sleep diary;\n5. Written informed consent from the participant and their parent\u002Fguardian (for those aged under 18);\n6. Being able to comply with the study protocol;\n7. Either not on ADHD medication or stabilized on medications for at least 6 months.\n\nExclusion criteria:\n\nAn adolescent who meets one or more of the following criteria will be excluded from the study:\n\n1. Substance abuse or dependence; a current or past history of manic or hypomanic episode, schizophrenia, ASD, organic mental disorders, or intellectual disabilities;\n2. Prominent medical condition affecting sleep (e.g., severe eczema, GERD);\n3. Clinically diagnosed sleep disorder other than insomnia disorder, such as narcolepsy, sleep-disordered breathing, and restless leg syndrome;\n4. Concurrent, regular use of medications(s) known to affect sleep continuity and quality including both prescribed medications (e.g., hypnotics, steroids) and over-the-counter OTC medications (e.g., melatonin, Traditional Chinese Medicine, TCM), except for ADHD stimulants;\n5. Ongoing psychological treatment for sleep problems;\n6. With hearing or speech deficit;\n7. Having a clinically significant suicidality (presence of suicidal ideation with a plan or an attempt).","10 Years","24 Years",{"count":193,"type":22},150,[25],"Attention-deficit\u002Fhyperactivity disorder (ADHD) is a neurodevelopmental disorder characterised by persistent inattention, hyperactivity, and impulsivity. In adolescents and young people, ADHD is commonly accompanied by insomnia and circadian delay. These co-occurring sleep and circadian disturbances may negatively affect daytime functioning and overall clinical outcomes. Although cognitive behavioural therapy for insomnia (CBT-I) is considered the first-line treatment for insomnia, and bright light therapy may help address circadian issues, their efficacy in adolescents with ADHD and comorbid insomnia and eveningness remains unexplored. This study aims to evaluate whether CBT-I, with or without bright light therapy, improves insomnia, sleep, and circadian as well as other clinical outcomes, and cognitive functioning in youths with ADHD and whether these interventions can also lead to improvements in mood and other clinical symptoms, as well as cognitive functioning.",[28,197,198,199,200],"ADHD","Eveningness","Chronotype","Treatment Effectiveness","2026-08-11",{"date":149,"type":43},{"date":204,"type":22},"2026-08-10",{"date":206,"type":22},"2029-08-31",{"name":49,"class":50},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":23,"phases":217,"briefSummary":218,"conditions":219,"keywords":222,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":51},"100578587","dream2heal-an-adaptive-stepped-care-intervention-for-chinese-cancer-survivors-with-mild-to-moderate-insomnia-100578587","NCT06813235","Dream2Heal: An Adaptive Stepped-care Intervention for Chinese Cancer Survivors With Mild-to-moderate Insomnia","Dream2Heal: A Pilot Sequential Multiple Assignment Randomized Trial (SMART) of an Adaptive Stepped-care Intervention for Chinese Cancer Survivors With Mild-to-moderate Insomnia","Inclusion Criteria:\n\n* Cantonese- or Mandarin-speaking Chinese patients diagnosed with curable breast, colorectal, or gynaecological cancer\n* Completed treatment (except endocrine therapy) within two years\n* Presenting with Pittsburgh Sleep Quality Index (PSQI) score of 6 to 11 indicating mild-to-moderate sleep disturbance\n\nExclusion Criteria:\n\n* Diagnosis of metastatic cancer\n* Current diagnosis of psychiatric disorder\n* Current diagnosis of another sleep disorder,\n* Have received psychological treatment specifically for sleep disturbance",{"count":216,"type":22},72,[25],"The primary objective of this feasibility study is to assess the feasibility and acceptability, and potential clinical significance of an adaptive stepped-care intervention for improving sleep quality among Chinese cancer patients with mild-to-moderate sleep disturbance, using a sequential multiple assessment randomized controlled trial (SMART) design.",[220,221],"Neoplasm","Sleep Disturbance",[223,224,225,226,227],"Sequential multiple assessment randomized controlled trial","sleep disturbance","cancer survivors","insomnia","Survivorship intervention",{"date":229,"type":43},"2026-08-13",{"date":231,"type":43},"2025-02-01",{"date":233,"type":22},"2027-02-02",{"name":49,"class":50},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":23,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":258},"100491468","managing-fear-of-cancer-progression-metacognition-based-vs-supportive-expressive-based-approaches-100491468","NCT05679518","Managing Fear of Cancer Progression Metacognition-based Vs Supportive-expressive Based Approaches","Managing Fear of Cancer Progression Metacognition-based Vs Supportive-expressive Based Approaches: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Cantonese- or Mandarin-speaking Chinese patients recently diagnosed with advanced or metastatic (i.e. stage III or IV) cancer\n* are the age of 18 years or above\n\nExclusion Criteria:\n\n* Patients with major communication difficulties\n* are being unwilling or unable to commit 6 psychotherapy sessions",{"count":243,"type":22},284,[25],"The present study aims to conduct a randomized controlled trial to assess the effect of CALM intervention and ConquerFear intervention on fear of cancer progression among Chinese patients diagnosed with advanced cancer.",[247,248,249,250,251],"Advanced or Metastatic Cancer","Fear of Cancer Progression","Metacognition-based Intervention","Supportive-expressive Based Intervention","Psychooncology",{"date":229,"type":43},{"date":254,"type":43},"2023-12-20",{"date":256,"type":22},"2027-06-30",{"name":49,"class":50},4,{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":23,"phases":268,"briefSummary":269,"conditions":270,"keywords":274,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":286},"100480315","a-self-management-based-survivorship-intervention-for-chinese-cancer-survivors-100480315","NCT05534386","A Self-management Based Survivorship Intervention for Chinese Cancer Survivors","How to Prevent Lost in Transition? - Adaptive Randomised Controlled Trial of a Self-management Based Survivorship Intervention for Chinese Cancer Survivors","Inclusion Criteria:\n\n* Cantonese- or Mandarin-speaking Chinese patients diagnosed curable cancer\n* have completed primary and adjuvant treatment within the past six months\n\nExclusion Criteria:\n\n* Patients diagnosed with metastatic cancer",{"count":267,"type":22},486,[25],"This study, using a sequential multiple assessment randomized controlled trial (SMART) approach, will evaluate a cancer survivorship care intervention on physical symptom distress, weight management, self-efficacy in managing cancer and health-related quality of life among Chinese patients recently completed curative cancer treatment.",[271,272,273],"Physical Symptom Distress","Weight Management","Neoplasms",[275,276,277,278,227,223,279],"Physical symptom distress","Weight management","Self-efficacy in managing cancer","Health-related quality of life","psychooncology",{"date":229,"type":43},{"date":282,"type":43},"2023-04-12",{"date":284,"type":22},"2027-12-31",{"name":49,"class":50},7,{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":23,"phases":296,"briefSummary":297,"conditions":298,"keywords":302,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":309,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":315},"100617211","acupressure-for-cough-in-lung-cancer-survivors-100617211","NCT07315672","Acupressure for Cough in Lung Cancer Survivors","Acupressure for Cough in Lung Cancer Survivors: A Randomized Controlled Trial","Inclusion Criteria:\n\n* be at least 18 years of age;\n* have a diagnosis of LC at any stage and of any pathological type;\n* have a cough symptom rating ≥3 on a 0 to 10 numeric rating scale within 7 days preceding enrollment;\n* can perform acupressure independently in daily activities;\n* be able to read Chinese and communicate in Cantonese or Mandarin;\n* be able to provide informed consent.\n\nExclusion Criteria:\n\n* have unstable chronic diseases other than LC;\n* have received acupressure or acupuncture within the three months preceding study enrollment;\n* have serious illnesses or other conditions that prevent the participants from following the intervention protocols;\n* have a life expectancy of less than 3 months;\n* Be currently participating in other research programs that may affect the outcomes under investigation.",{"count":295,"type":22},80,[25],"The goal of this randomized controlled trial is to examine the effect of an acupressure intervention in alleviating cough and reducing co-occurring symptoms (dyspnea, cough, and fatigue) in patients with lung cancer.\n\nThe hypotheses are:\n\n1. Acupressure can alleviate cough in lung cancer survivors;\n2. Acupressure can reduce a cough-related symptom cluster (dyspnea-cough-fatigue) experienced by lung cancer survivors;\n3. Acupressure can reduce the symptom burden and improve the health-related quality of life and functional capacity of lung cancer survivors experiencing cough.\n\nParticipants will:\n\nReceive acupressure for 8 weeks or receive an education booklet; Keep a diary of their acupressure practice and symptoms; Be assessed at baseline (T0), early intervention (T1), post-intervention (T2), and 8 weeks after the intervention period (T3).",[299,95,300,301],"Lung Cancer (Diagnosis)","Coughing","Symptom Cluster",[95,303,304,305,301,306,307,308],"Cough","Lung Cancer","Dyspnea","Symptom Burden","Fatigue","Quality of Life",{"date":201,"type":43},{"date":311,"type":43},"2026-03-09",{"date":313,"type":22},"2027-02",{"name":49,"class":50},2,{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":12,"sex":138,"minAge":324,"maxAge":165,"enrollmentInfo":325,"targetDuration":4,"studyType":23,"phases":326,"briefSummary":327,"conditions":328,"keywords":331,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":340,"leadSponsor":342,"locationsCount":51},"100651392","transurethral-thermodilatation-vs-prostatic-urethral-lift-for-moderate-to-severe-bph-100651392","NCT07759752","Transurethral Thermodilatation vs. Prostatic Urethral Lift for Moderate-to-Severe BPH","Transurethral Thermodilatation Versus Prostatic Urethral Lift for Moderate-to-Severe BPH: A Randomised Controlled Non-Inferiority Trial","THRIVE","Inclusion Criteria:\n\nParticipants must satisfy ALL of the following:\n\n* Male, aged ≥ 50 and ≤ 80 years\n* Moderate-to-severe LUTS due to BPH: IPSS total score ≥ 13 at screening\n* Peak urinary flow rate (Qmax) ≥ 5 and ≤ 12 mL\u002Fs with minimum voided volume ≥ 125 mL on free uroflowmetry. The lower Qmax bound of ≥ 5 mL\u002Fs excludes near-complete retention with likely detrusor underactivity, as adopted in the Rezūm pivotal trial\n* Prostate volume 30-80 g by transrectal ultrasound (TRUS) or multiparametric MRI, consistent with the L.I.F.T. and Rezūm pivotal study ranges\n* Post-void residual (PVR) ≤ 250 mL by bladder ultrasound\n* Currently on, or has previously tried, medical therapy for BPH (alpha-blocker and\u002For 5-alpha-reductase inhibitor) for ≥ 4 weeks with inadequate symptom control, or documented intolerance to medical therapy\n* Able to provide written informed consent\n* Able and willing to attend all study follow-up visits\n\nExclusion Criteria:\n\nParticipants will be excluded if ANY of the following apply:\n\n* Intravesical prostatic protrusion \\> 10 mm on TRUS.\n* Presence of metallic pelvic implants, penile prosthesis, femoral metallic implant, cardiac pacemaker, or implantable cardioverter-defibrillator.\n* Previous transurethral resection of the prostate (TURP), HoLEP, or any prior endoscopic prostate surgery.\n* Prior pelvic radiation therapy.\n* Prostatic urethral length \\\u003C 1.2 cm or \\> 5.5 cm.\n* Confirmed or suspected prostate carcinoma (unresolved elevated PSA without negative biopsy, or any known malignancy).\n* Active urinary tract infection at screening.\n* Bladder stone, bladder tumour, or suspected bladder malignancy.\n* Urethral stricture or bladder neck contracture precluding catheter passage (Foley ≥ 18 Fr).\n* Neurogenic bladder or known clinically significant detrusor underactivity.\n* History of acute urinary retention.\n* Coagulopathy or therapeutic anticoagulation that cannot be bridged perioperatively.\n* Renal impairment: eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m² (Cockcroft-Gault).\n* Desire to preserve fertility (due to risk of retrograde ejaculation with either device).\n* IPSS QoL bother score \\\u003C 3 (patient not sufficiently bothered to warrant procedural intervention).\n* Participation in another interventional clinical trial within the preceding 30 days.","50 Years",{"count":193,"type":22},[25],"This clinical trial aims to determine whether Prolieve® (microwave with balloon dilation) is as effective as UroLift® (prostate implants) for treating moderate-to-severe lower urinary tract symptoms in men aged 50-80 with enlarged prostates (BPH) who have failed oral medications.\n\nThe main questions are:\n\n1. Is Prolieve non-inferior to UroLift in improving IPSS symptom scores at 3 months?\n2. Does Prolieve cause less pain and avoid the need for injected anaesthesia?\n\nResearchers will compare Prolieve (LA urethral gel only, no injections) against UroLift (LA urethral gel with or without local anaesthetic injection) to see if Prolieve offers similar relief with better tolerability.\n\nParticipants will stop their BPH medications for 2-4 weeks, undergo one of the two same-day office procedures, and attend follow-ups at 1, 3, 6, and 12 months for symptom scores, flow tests, and bladder scans.",[329,330],"BPH (Benign Prostatic Hyperplasia)","LUTS(Lower Urinary Tract Symptoms)",[332,333,334,335],"Transurethral Thermodilatation","Prostatic Urethral Lift","BPH","LUTS","2026-08-06",{"date":338,"type":43},"2026-08-12",{"date":336,"type":22},{"date":341,"type":22},"2029-11-05",{"name":49,"class":50},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":349,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":23,"phases":352,"briefSummary":353,"conditions":354,"keywords":356,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":367,"locationsCount":51},"100523025","a-hybrid-effectiveness-implementation-evaluation-on-programs-promoting-healthy-aging-with-sport-exercise-phase-program-100523025","NCT06090253","A Hybrid Effectiveness-implementation Evaluation on Programs Promoting Healthy Aging With Sport Exercise (PHASE Program)","Inclusion Criteria:\n\n* Age above 60 years\n\nExclusion Criteria:\n\n* Any contraindication to exercise training",true,{"count":351,"type":22},1940,[25],"The goal of this clinical trial is to provide scientific evaluation on the effects of Promoting Healthy Aging with Sport Exercise (PHASE) Programs on the functional capacity of older. Based on the participants' mental well-being and physical health status, they will be provided with several tailored exercise intervention, including 1) football training; 2) gero-technology enhanced multi-component exercise; 3) slow sports and exercise; 4) walking exercise; 5) home-based exercise. A control group is also recruited and provided with no exercise intervention.",[355],"Ageing Well",[357,358,359,360],"Ageing","Exercise","Community-dwelling","Functional Capacity","2026-08-02",{"date":363,"type":43},"2026-08-05",{"date":365,"type":43},"2023-09-01",{"date":284,"type":22},{"name":49,"class":50},{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":376,"minAge":60,"maxAge":164,"enrollmentInfo":377,"targetDuration":4,"studyType":23,"phases":379,"briefSummary":381,"conditions":382,"keywords":384,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":315},"100635308","phase-3-yulinzhu-for-women-with-diminished-ovarian-reserve-100635308","NCT07550998","Yulinzhu for Women With Diminished Ovarian Reserve","Yulinzhu for Women With Diminished Ovarian Reserve: a Randomized, Waiting-list Controlled, Crossover Trial","DOR","Inclusion Criteria:\n\n1. Women aged 18-40, with regular menstruation (cycle from 21 to 35 days) and reduced fertility (infertility, early miscarriage, recurrent pregnancy loss, recurrent implantation failure, etc.) ;\n2. Tests of ovarian reserve within 6 months:\n\n   1. AMH \\\u003C 1.1 ng\u002Fml or (any day in cycle, refer to laboratory standards);\n   2. AFC \\\u003C 7 follicles or (any day in cycle);\n   3. Received \\\u003C3 cycles of IVF in public sector;\n3. Subject has no history of allergy to TCM;\n4. Subjects agree to receive IVF treatment upon the completion of this research within 12 weeks if they are not pregnant spontaneously; and\n5. As diagnosed by Chinese Medicine practitioner through four diagnostic methods, suitable to receive Yulinzhu.\n\nExclusion Criteria:\n\n1. Previous history of a unilateral or bilateral oophorectomy;\n2. Recent administration of TCM for DOR within 3 months;\n3. Diagnosis of pregnancy, premature ovarian failure, residual follicles, cysts or space-occupying lesions in the ovary, pelvic inflammatory disease or polycystic ovary syndrome; and\n4. Cancer, untreated thyroid dysfunction, severe cardiovascular\u002Fcerebrovascular diseases, severe liver\u002Fkidney diseases or hematopoietic system diseases.\n5. Subjects are allowed to withdraw from the trial for one of the following reasons:\n\n(1) The patient fails to complete treatment due to safety or medical reasons; (2) The patient fails to follow treatment guidelines; (3) The patient is unwilling to continue treatment for any reason.","FEMALE",{"count":378,"type":22},60,[380],"PHASE3","This is a randomized waiting-list controlled crossover trial carried out to investigate the efficacy of traditional Chinese medicine (TCM) for DOR and its potential beneficial effects on fertility. Subjects' (1) Ovarian function (AMH, FSH), (2) Bilateral AFC as shown in pelvic ultrasound, and (3) Traditional Chinese Medicine Symptom Score (TCMSS) will be recorded. It is hypothesized that a 12-week course (5 days medication per week) of TCM herbal therapy for DOR patients will improve one or more of the above aspects when compared to the waiting-list control group.",[383],"Diminished Ovarian Reserve (DOR)",[385,386,387],"Chinese Medicine","diminished ovarian reserve","Yulinzhu","2026-07-30",{"date":152,"type":43},{"date":391,"type":43},"2026-04-24",{"date":393,"type":22},"2027-10-31",{"name":49,"class":50},{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":349,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":23,"phases":405,"briefSummary":406,"conditions":407,"keywords":409,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":51},"100623412","the-existential-cognitive-intervention-to-enhance-positive-aspect-of-caregiving-excite-pac-in-a-dementia-context-100623412","NCT07396298","The Existential Cognitive Intervention to Enhance Positive Aspect of Caregiving (EXCITE-PAC) in a Dementia Context","The Effects and Mediating Mechanism of the Existential Cognitive Intervention to Enhance Positive Aspect of Caregiving (EXCITE-PAC) in a Dementia Context: A Sequential Mixed Method Study","EXCITE-PAC","Inclusion Criteria:\n\n* family carers of Chinese PLwDs diagnosed at least six months previously\n* caregiving for ≥ 4 hours\u002Fday\n* Chinese-speaking\n* have a mobile device to access virtual meeting via Go-To-Meeting or Zoom\n* consent to participate\n\nExclusion Criteria:\n\n* NA",{"count":404,"type":22},304,[25],"Although research evidence is emerging on the co-existence of a positive caregiving experience in the physically and psychosocially taxing dementia care context, little attention has been paid to promoting the positive aspects of caregiving (PAC) among family carers. We adopt the paradigm of existential positive psychology, integrating cognitive behavioural theory, construal level theory, and Antonovsky's theory of salutogenesis to develop an existential-cognitive intervention to enhance positive aspects of caregiving (EXCITE-PAC), and thereby improve the health outcomes of family carers of people living with dementia (PLwD). A randomised controlled trial is proposed to evaluate the effects of EXCITE-PAC on carers' health and to examine whether any such effects are mediated through changes in PAC. Post-trial interviews with carers will further elucidate their experiences of the intervention and their perceptions of its impact.\n\nThe proposed study will yield important theoretical and public health advances. Theoretically, it will test the validity of an integrative paradigm designed to enrich the life space of family carers in the context of dementia care by increasing their opportunities to experience PAC. If supported, this paradigm can complement the dominant stress-coping framework and help reshape the caregiving experience of family carers of PLwD. From a public health perspective, if EXCITE-PAC proves effective, it will respond to the WHO Global Action Plan on Dementia by promoting carers' health. Crucially, by enriching carers' PAC through empowering them to internalise a new perspective on dementia caregiving, the intervention has the potential to foster more sustainable and evolving positive effects on role adaptation and health status. Together with a comprehensive evaluation of outcomes and end-user experiences, the knowledge generated from this study can be readily translated into dementia care service development and policy. This is a pilot mixed-method study comprising a randomised controlled trial and a post-trial qualitative interview. The inclusion criteria are: i) family carers of Chinese PLwDs diagnosed at least six months previously; ii) caregiving for ≥ 4 hours\u002Fday; iii) Chinese-speaking; iv) have a mobile device to access virtual meetings via Go-To-Meeting or Zoom; and iv) consent to participate. After the baseline outcome evaluation, they will be randomised to receive the 12-week EXCITE-PAC program or usual care. The program comprises three phases, including i) face-to-face home visit, ii) group-based virtual meetings, and iii) telephone follow-ups. The outcome evaluation on i) PAC, ii) Health-related quality of life (HRQoL), iii) depression, iv) self-efficacy in caregiving, and v) meaning-making upon programme completion will be assessed at baseline, in the 12th and 18th weeks. Qualitative interviews will be conducted.",[408],"Dementia Caregiver",[410,411,412],"Positive aspect of caregiving","dementia caregiver","existential-cognitive intervention",{"date":152,"type":43},{"date":415,"type":22},"2026-09-15",{"date":417,"type":22},"2028-06-30",{"name":49,"class":50},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":23,"phases":428,"briefSummary":429,"conditions":430,"keywords":437,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":445,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":51},"100619531","the-effect-of-volunteer-engaged-lifestyle-optimisation-via-icope-on-sarcopenia-in-older-adults-velo-s-100619531","NCT07345832","The Effect of Volunteer-Engaged Lifestyle Optimisation Via ICOPE on Sarcopenia in Older Adults (VELO-S)","The Effect of Volunteer-Engaged Lifestyle Optimisation Via ICOPE on Sarcopenia in Older Adults (VELO-S): A Randomised Controlled Trial","Inclusion Criteria:\n\n1. aged 60 or above\n2. Pseudo-Sarcopenia as indicated by a score on SARC-CaIF ≥11, OR sarcopenia according relative BIA-based appendicular skeletal mass\u002F height (Men: \\\u003C7 kg\u002Fm2; women: \\\u003C5.7 kg\u002Fm2), OR handgrip strength on dominant hand (male \\\u003C28 kg, female \\\u003C18 kg) (Chen et al., 2025)\n3. the ability to use a smartphone, electronic tablet, or computer\n4. consent to participate\n\nExclusion Criteria:\n\n1. having medical conditions contradictory to physical activity including unstable cardiovascular and orthopaedic conditions\n2. engaging in other structured health promotion program involving physical activity and nutritional enhancement",{"count":427,"type":22},200,[25],"Sarcopenia prevention and management are highly prioritised goals in the Healthy Ageing agenda. The study aims to: 1) evaluate the effects of the digital-enhanced, volunteer-engaged collaborative care pathway to improve sarcopenia, reduce fall risk, and increase health-related quality of life (HRQL) among community-dwelling older adults with risk of, or diagnosed with, sarcopenia; 2) evaluate whether the volunteers who received health coach capacity training and supported the intervention experienced health benefits across time; 3) explore the engagement experiences and perceived effects of elderly participants with sarcopenia during the program; 4) evaluate the intervention implementation process and effects from the perspectives of social care workers.",[431,432,433,434,435,436],"Sarcopenia","Sarcopenia in Elderly","Fall Prevention in Healthy Aging","Frailty Syndrome","Malnutrition Elderly","Frailty",[438,439,440,441,442,443,444],"sarcopenia","elderly","frailty","fall prevention","malnutrition","health-related quality of life","digital intervention",{"date":152,"type":43},{"date":447,"type":43},"2026-02-01",{"date":449,"type":22},"2027-09-30",{"name":49,"class":50},{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":458,"enrollmentInfo":459,"targetDuration":4,"studyType":23,"phases":460,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":51},"100649504","improv-comedy-to-reduce-anxiety-and-improve-mental-well-being-in-young-chinese-adults-in-hong-kong-100649504","NCT07737821","Improv Comedy to Reduce Anxiety and Improve Mental Well-Being in Young Chinese Adults in Hong Kong","An Improv Comedy Intervention to Reduce Anxiety and Enhance Mental Well-Being in Chinese Emerging Adults in Hong Kong: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Ethnic Chinese, fluent in spoken Mandarin and able to read Chinese\n* Never married and without children\n* No current or past diagnosis of any mental disorder (e.g. anxiety disorders, depressive disorders, bipolar disorder, psychotic disorders)\n* Mild to moderate anxiety symptoms (defined as a GAD-7 total score between 5 and 14)\n* No prior experience of formal performance training in drama\n* Availability to attend at least 3 out of 4 weekly sessions over the 4-week intervention period upon enrolment\n\nExclusion Criteria:\n\n* Unstable or severe chronic physical illness that would contraindicate participation in group activities or light-to-moderate physical movement (e.g., uncontrolled hypertension, severe asthma, acute cardiovascular events within the past 6 months)\n* Moderately severe to severe depression symptoms (defined as a PHQ-9 total score greater than 14)\n* Suicidal ideation (defined as a score greater than 0 on item 9 of the PHQ-9)\n* Potential risky drinking behavior (defined as AUDIT-C total score greater than 4)","29 Years",{"count":193,"type":22},[25],"The goal of this clinical trial is to learn if improv comedy helps reduce anxiety symptoms and improve mental well-being in Chinese young adults in Hong Kong. The main questions it aims to answer are:\n\n1. Does improv comedy reduce anxiety symptoms?\n2. Does improv comedy improve mental well-being?\n\nResearchers will compare participants who join the improv comedy workshops to participants who are placed on a waiting list to receive the workshops later, to see if improv comedy reduces anxiety and improves mental well-being.\n\nParticipants will:\n\n1. Attend weekly three-hour improv comedy workshops for 4 consecutive weeks\n2. Complete four assessments and brief reflections during or around the workshop sessions\n3. Take part in up to two individual interviews (optional)",[463,464],"Anxiety","Mental Health","2026-07-28",{"date":388,"type":43},{"date":468,"type":22},"2026-08-15",{"date":470,"type":22},"2028-08-31",{"name":49,"class":50},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":478,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":138,"minAge":60,"maxAge":4,"enrollmentInfo":480,"targetDuration":4,"studyType":23,"phases":481,"briefSummary":482,"conditions":483,"keywords":487,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":51},"100649459","emindexcare-for-prostate-cancer-patients-undergoing-active-treatment-100649459","NCT07735273","eMindExCare for Prostate Cancer Patients Undergoing Active Treatment","Effects of Integrated Mindfulness and Exercise eHealth Intervention (eMindExCare) on Sleep, Fatigue, and Physical Activity Among Prostate Cancer Patients Undergoing Active Treatment: A Feasibility Trial","eMindExCare","Inclusion Criteria:\n\n1. Diagnosed with prostate cancer, stage I, II, or III.\n2. Aged older than 18 years.\n3. Undergoing active treatment, including chemotherapy, radiotherapy, or hormone therapy, at Prince of Wales Hospital.\n4. Able to communicate and read Chinese.\n5. Has access to the Internet and a computer or tablet.\n6. Demonstrates clinically impaired sleep quality or insufficient physical activity as measured by ActiGraph. Clinically impaired sleep quality may include study-defined sleep disturbance criteria such as total sleep time less than 6.5 hours, sleep onset latency greater than 30 minutes, awakenings lasting greater than 5 minutes, or wake after sleep onset greater than 30 minutes.\n\nExclusion Criteria:\n\n1. Diagnosed with more than one primary cancer.\n2. Has metastatic disease.\n3. Has participated in a mindfulness programme.\n4. Is sufficiently physically active at the time of recruitment.\n5. Has a mental condition, World Health Organization\u002FEastern Cooperative Oncology Group performance status greater than 2, a physical disability that prevents participation in the intervention, or any other health problem that rules out regular physical activity as determined by the treating physician.",{"count":378,"type":22},[25],"This feasibility randomized controlled trial will assess the acceptability, feasibility, and preliminary effects of an integrated mindfulness and exercise eHealth intervention, eMindExCare, among prostate cancer patients undergoing active treatment in Hong Kong. Participants will be randomized in a 1:1 ratio to either an 8-week eMindExCare intervention or an enhanced health education attention-control programme. eMindExCare integrates culturally adapted Cantonese mindfulness practices with home-based aerobic and resistance exercise delivered through Zoom, supported by home practice, exercise logs, and weekly reminders. The enhanced health education control programme will match the intervention group in contact time and engagement but will not include progressive aerobic training, resistance-band prescription, stationary bike provision, or a structured mindfulness curriculum. Feasibility and acceptability outcomes will include eligibility, consent, randomization, attendance, retention, questionnaire completion, missing data, and adverse events. Preliminary outcomes will include sleep quality, fatigue, pain, physical activity, mindfulness, motivation for exercise, and quality of life assessed at baseline, immediately post-intervention at week 8, and 3 months post-intervention.",[484,221,307,485,486],"Prostate Cancer","Physical Inactivity","Pain",[484,488,478,148,489,490,491,492,224,493,494,495,496,497,498],"prostate neoplasms","exercise","physical activity","eHealth","sleep quality","fatigue","pain","quality of life","feasibility trial","pilot randomized controlled trial","Hong Kong",{"date":500,"type":43},"2026-07-29",{"date":502,"type":22},"2026-10-01",{"date":504,"type":22},"2028-09-30",{"name":49,"class":50},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":514,"enrollmentInfo":515,"targetDuration":4,"studyType":23,"phases":517,"briefSummary":518,"conditions":519,"keywords":522,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":51},"100649569","repetitive-transcranial-magnetic-stimulation-for-people-with-etomidate-addiction-stop-e-rtms-x-etomidate-100649569","NCT07736742","Repetitive Transcranial Magnetic Stimulation for People With Etomidate Addiction (SToP-E-rTMS x Etomidate)","Substance Misuse To Psychiatric Disorders for Etomidate -Repetitive Transcranial Magnetic Stimulation for People With Etomidate Addiction: a 6-month, Double-blind, Randomized, Sham-controlled Trial","SToP-E","Inclusion Criteria:\n\n* Able to read and communicate in English and\u002For Chinese\n* Able to give informed consent and\u002For able to provide an informed consent from the legal guardian (if applicable)\n* Using etomidate and\u002For its related analogues as the primary psychoactive substance of abuse\n* Suffering from etomidate addiction as defined by:\n\n  1. Etomidate Use Disorder classified under \"Sedative-, Hypnotic-, or Anxiolytic Use Disorder\" according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) with severity ≥ 1, or\n  2. Harmful Use or Dependence for etomidate classified under \"Mental and behavioral disorders due to use of sedatives or hypnotics\" according to the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10), or\n  3. Hazardous use, harmful use or dependence classified under \"Hazardous use of sedatives, hypnotics or anxiolytics\" or \"Disorders due to use of sedatives, hypnotics or anxiolytics\" according to the Clinical descriptions and diagnostic requirements for International Classification of Diseases 11th Revision (ICD-11) mental, behavioral, and neurodevelopmental disorders.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Unable to read English or Chinese\n* Unable to give informed consent\n* Had been diagnosed with the following disorders including:\n\n  1\\. Neurodevelopmental Disorders:\n* DSM-5: Intellectual Disabilities, Communication Disorders, Specific Learning Disorder, Autism Spectrum Disorder and Motor Disorders\n* International Statistical Classification of Diseases and Related Health Problems 11th Revision (ICD-11): Disorders of intellectual development (6A00), Developmental speech or language disorders (6A01), Autism spectrum disorder (6A02), Developmental learning disorder (6A03), Developmental motor coordination disorder (6A04), Stereotyped movement disorder (6A06), Primary tics or tic disorders (8A05.0)\n* Other DSM-5 defined Substance Use Disorder greater than moderate in severity (i.e., severity score ≥4)\n* Neurocognitive Disorders (DSM-5, or ICD-11 6D70-72 \\& 6D80-86) 2. Contra-indicated to undergo rTMS:\n* with electronic and\u002For magnetic implants (e.g., pacemaker, implantable cardioverter defibrillator \\[ICD\\], cerebral shunts, cochlear implant, etc.)\n* with metallic or mechanic fragments (e.g., screws, plates, stents, clips, etc.)\n* pregnant\n* with any known or history of neurological conditions including cerebral vascular accidents (CVA), epilepsy, brain tumor or space occupying lesion, etc.\n* poorly controlled or unstable diabetes mellitus\n* receiving unstable dose(s) of antipsychotics, antidepressants, benzodiazepines and\u002For anticonvulsants in the past 3 months","45 Years",{"count":516,"type":22},40,[25],"The goal of this clinical trial is to learn if high-frequency rTMS works to treat etomidate addiction in adults. It will also learn about the safety and tolerability of rTMS. The main questions it aims to answer are:\n\n* Does active rTMS reduce craving, amount of etomidate use, frequency of etomidate use, and severity of etomidate use disorder?\n* Does active rTMS improve cognitive biases related to delayed reward discounting and risk sensitivity?\n* What side-effects do participants have when receiving rTMS?\n\nResearchers will compare active rTMS to sham rTMS to see if active rTMS works to treat etomidate addiction.\n\nParticipants will:\n\n* Receive active rTMS or sham rTMS over 4 weeks\n* Complete 20 rTMS sessions in total\n* Visit the clinic for treatment sessions and follow-up assessments\n* Complete assessments of etomidate use, craving, withdrawal symptoms, mood symptoms, cognition, and decision-making\n\nAttend follow-up assessments up to 6 months after baseline",[520,521],"Etomidate Use Disorder","Repetitive Transcranial Magnetic Stimulation (rTMS)",[523,524,525],"Etomidate","rTMS","addiction","2026-07-26",{"date":388,"type":43},{"date":529,"type":22},"2026-09-01",{"date":531,"type":22},"2029-03-31",{"name":49,"class":50},{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":4,"eligibilityCriteria":539,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":540,"targetDuration":4,"studyType":23,"phases":542,"briefSummary":543,"conditions":544,"keywords":547,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":557,"completionDateStruct":558,"leadSponsor":560,"locationsCount":51},"100648370","point-of-care-capillary-hba1c-testing-for-type-2-diabetes-screening-among-at-risk-individuals-in-rural-dali-china-100648370","NCT07718867","Point-of-care Capillary HbA1c Testing for Type 2 Diabetes Screening Among At-risk Individuals in Rural Dali, China","Effectiveness and Cost-Effectiveness of Point-of-care Capillary HbA1c Testing for Type 2 Diabetes Screening Among At-risk Individuals in Rural Dali, Yunnan, China: A Cluster Randomised Controlled Trial","Inclusion Criteria:\n\n* Aged 18 years or above;\n* Permanent residents of Dali City who have lived locally for at least six consecutive months;\n* Registered as rural residents;\n* No known history of diabetes;\n* Meet at least one of the high-risk criteria for T2DM specified in the Chinese Guidelines for the Prevention and Treatment of Diabetes issued by the Chinese Diabetes Society;\n* Able to understand the study information and provide written informed consent.\n\nExclusion Criteria:\n\n* Known history of T2DM or currently receiving glucose-lowering treatment;\n* HbA1c testing with a clear result within the past three months, or completion of standardised diabetes screening within the past six months;\n* Pregnant or breastfeeding at the time of recruitment;\n* Active thyroid disease or other active endocrine disorders at recruitment, such as Cushing's syndrome or acromegaly;\n* Known haemoglobinopathy, severe anaemia, recent acute blood loss, or history of blood transfusion or blood donation within the past three months;\n* Currently receiving treatment that may substantially affect interpretation of HbA1c, such as erythropoietin therapy or recent high-dose iron therapy.",{"count":541,"type":22},720,[25],"This project aims to compare Point-of-care capillary HbA1c (POC-cHbA1c) testing and fingerstick random blood glucose (RBG) testing in terms of type 2 diabetes detection rate and cost-effectiveness, in order to optimise current screening strategies for rural populations at high risk of diabetes in rural Dali, China, and to improve treatment adherence and self-management among people with diabetes.",[545,546],"Type 2 Diabetes","Pre-diabetes",[548,549,550,551,552,553,554],"POCT","HbA1c","Diabetes screening","Effectiveness","Cost-effectiveness","Rural China","Cluster randomised controlled trial","2026-07-25",{"date":465,"type":43},{"date":465,"type":22},{"date":559,"type":22},"2027-12-30",{"name":49,"class":50},{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":18,"minAge":567,"maxAge":4,"enrollmentInfo":568,"targetDuration":4,"studyType":23,"phases":570,"briefSummary":572,"conditions":573,"keywords":579,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":585,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":315},"100630074","phase-4-the-effect-of-dapagliflozin-on-exercise-and-cardiac-functional-status-of-patients-after-fontan-procedure-100630074","NCT07482943","The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure","Inclusion Criteria:\n\n* Patients with a functional single ventricle and who have undergone Fontan procedure\n* Adolescents aged ≥ 12 years with body weight ≥30kg and adults\n\nExclusion Criteria:\n\n* Planned cardiac and\u002For non-cardiac surgery in 3 months\n* Arrhythmias requiring change in therapy in recent 6 months\n* Intervention procedure within 6 months prior to enrollment\n* Documented structural abnormalities of the Fontan circulation\n* Chronic kidney disease stages 4 to 5\n* Inability to perform cardiopulmonary test\n* Recent use of SGLT2 inhibitors within 6 months\n* Known hypersensitivity to SGLT2 inhibitors\n* History of diabetic ketoacidosis\n* Recent symptomatic hypoglycaemia within 6 months\n* Insulin dependent diabetes mellitus\n* History of perineum infection\n* Recent urinary tract infection within 6 months\n* Recent genital infection within 6 months\n* Other known contraindications to SGLT2 inhibitor\n* Pregnancy or breast feeding","12 Years",{"count":569,"type":22},30,[571],"PHASE4","While the Fontan operation improves survival for patients with a functional single ventricle, complications like heart failure remain prevalent during follow-up, causing frequent hospitalizations and reduced quality of life. Currently, there are no evidence-based heart failure therapies or guidelines for patients with Fontan palliation. There is growing interest in using sodium-glucose cotransporter 2 inhibitors (SGLT2i) to optimize cardiac conditions in this group. SGLT2i's observed benefits relate to protective effects on cardiac energy metabolism, renal function, sympathetic activation, inflammation, oxidative stress, erythropoiesis, and vascular function. Therefore, SGLT2i may represent a new therapeutic agent to improve exercise capacity and ventricular function in patients with Fontan circulation.\n\nThis prospective, open-label, single-arm clinical trial investigates the FDA-approved drug dapagliflozin. An open-label design is utilized due to the relatively small cohort of patients with complex underlying hearts. The trial will be conducted at Hong Kong Children's Hospital (the sole pediatric cardiology center in Hong Kong) and Queen Mary Hospital (the largest tertiary referral center for adult congenital heart patients). The total study duration is 2 years.\n\nSubjects will participate for 3 months, receiving oral dapagliflozin 10mg once daily. The primary endpoint is VO2 max (maximum rate of oxygen consumption) during cardiopulmonary exercise testing at 3 months. Secondary assessments include questionnaires, history taking, physical examinations, 12-lead electrocardiogram, blood tests, echocardiography, bioelectrical impedance analysis, and urine pregnancy tests.\n\nIf the hypothesis holds true, clinical translation of this project will: i) Improve long-term outcomes and quality-of-life for Fontan patients, reducing the healthcare burden from repeated heart failure hospitalizations; ii) Revolutionize the management of Fontan-associated heart failure by introducing SGLT2i as a novel, evidence-based therapy locally and globally; iii) Pave the way for multicenter international trials evaluating SGLT2i in the Fontan population and broader congenital heart diseases.",[574,575,576,577,578],"Fontan","Heart Failure","Dapagliflozin","Cardiovascular Diseases","Sodium-GLucose coTransporter-2 Inhibitors",[580,581,582,583,584],"fontan","heart failure","dapagliflozin","Sodium-glucose cotransporter 2 (SGLT2) inhibitor","Congenital heart disease",{"date":465,"type":43},{"date":587,"type":43},"2026-07-01",{"date":589,"type":22},"2028-07",{"name":49,"class":50},{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":4,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":18,"minAge":567,"maxAge":191,"enrollmentInfo":598,"targetDuration":4,"studyType":23,"phases":600,"briefSummary":601,"conditions":602,"keywords":604,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":613,"leadSponsor":615,"locationsCount":4},"100610693","cognitive-behavioural-therapy-for-insomnia-among-young-people-with-moderate-level-of-mental-distress-in-hong-kong-100610693","NCT07230899","Cognitive Behavioural Therapy for Insomnia Among Young People With Moderate Level of Mental Distress in Hong Kong","A Randomized Controlled Trial of Cognitive Behavioural Therapy for Insomnia Among Young People With Moderate Level of Mental Distress in Hong Kong","Inclusion Criteria:\n\n* JC LevelMind @ Community users at least at risk for mild mental distress (Tier 2), with K6 scores above or equal to 11, or clinicians' endorsement after reviewing the case to have other issues\u002Fproblems\n* Aged between 12 and 24 years\n* Insomnia Severity Index (ISI) score greater than 7\n* Sufficiently proficient in Chinese to comprehend verbal instructions\n* Able to provide written informed consent (parental consent for participant aged 12-17)\n\nExclusion Criteria:\n\n* Young people with mild distress (K6 scores between 0 and 10)\n* Known diagnosis of intellectual disability\n* Organic brain disorder\n* Established psychiatric diagnosis\n* Current substance abuse\n* Receiving other structured psychological therapies such as module-based psychological therapy, mentalization-based therapy, low-intensity online interventions, cognitive-behavioral therapy, narrative therapy, mindfulness, or art-informed therapy within the hub setting or any others outside the hub setting\n* Presence of current or active suicidal ideation or attempts",{"count":599,"type":22},160,[25],"This randomized controlled trial (RCT) aims to evaluate the effectiveness of a Cognitive Behavioral Therapy for Insomnia (CBTi) intervention in enhancing sleep quality, overall quality of life, functional ability, and reducing mental distress among at-risk youths in Hong Kong. Participants are youths with moderate mental health concerns, indicated by K6 scores ranging from 11 to 14.\n\nThe study involves 160 participants who will be randomly assigned to either the intervention group or a wait-list control group. Participants assigned to the intervention group will receive six weekly face-to-face sessions led by trained youth workers, while those in the control group will receive the same intervention after the initial follow-up period.\n\nParticipants will be evaluated at baseline, post-intervention, and one-month follow-up. An interim analysis is built for the sake of evaluation of the collected data from the ongoing trial, in which the primary research question is addressed, and which has the potential for modifying the conduct of the study. Furthermore, a qualitative follow-up will be conducted after the trial, involving both participants and the workers delivering the CBTi intervention. This qualitative component aims to gather feedback on participants' experiences, and inform potential revisions to enhance future implementation.\n\nIt is hypothesized that youths receiving the CBTi intervention will show significantly greater improvements in sleep quality, quality of life, and functioning, along with reductions in mental distress, as well as depressive and anxiety symptoms, compared to those in the wait-list control group.",[603,28],"Mental Distress",[605,606,607,608],"cognitive behavioural therapy for insomnia","youths","mental distress","randomised controlled trial","2026-07-24",{"date":611,"type":43},"2026-07-27",{"date":45,"type":22},{"date":614,"type":22},"2027-08-31",{"name":49,"class":50},{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":4,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":623,"targetDuration":4,"studyType":23,"phases":624,"briefSummary":625,"conditions":626,"keywords":627,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":632,"lastUpdatePostDateStruct":633,"startDateStruct":634,"completionDateStruct":635,"leadSponsor":636,"locationsCount":51},"100647545","nurse-led-digital-cognitive-behavioral-therapy-for-insomnia-dcbt-i-in-university-students-with-mild-to-moderate-mental-health-problems-100647545","NCT07711769","Nurse-led Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) in University Students With Mild to Moderate Mental Health Problems","Nurse-led Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) in University Students With Mild to Moderate Mental Health Problems: a Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Students aged ≥ 18 years from 22 local higher education institutions (University or Colleges) listed in Education Bureau.\n* Screening score indicating mild to moderate anxiety or depression, defined as a GAD-7 score of 5-14 and\u002For a PHQ-9 score of 5-14 at baseline.\n* Screened positive for insomnia symptoms using the Sleep Condition Indicator (SCI) and meeting DSM-5 diagnostic criteria for insomnia disorder.\n* Reporting a self-reported sleep efficiency of less than 85% over the past month.\n* Able to communicate in Chinese.\n\nExclusion Criteria:\n\n* Participants who self-reported diagnosis of epilepsy, schizophrenia, or bipolar disorder\n* Participants who self-reported current suicidal ideation with intent or a suicide attempt within the past 2 months\n* Participants who self-reported current receipt of psychological or behavioral treatment for insomnia from a health professional\n* Participants who self-reported participation in an online or digital insomnia treatment programme at the time of enrolment.",{"count":62,"type":22},[25],"This study aims to evaluate the feasibility, acceptability, and potential effectiveness of a nurse-led digital cognitive behavioral therapy for insomnia (dCBT-I) via large language model based-chatbot among university students with mental health problems.",[464],[628,226,629,630,631],"Cognitive Behavioral Therapy for Insomnia","large language model","chatbot","university student","2026-07-23",{"date":609,"type":43},{"date":529,"type":22},{"date":393,"type":22},{"name":49,"class":50},{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":641,"acronym":4,"eligibilityCriteria":642,"healthyVolunteers":349,"sex":18,"minAge":514,"maxAge":4,"enrollmentInfo":643,"targetDuration":4,"studyType":23,"phases":645,"briefSummary":646,"conditions":647,"keywords":649,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":655,"lastUpdatePostDateStruct":656,"startDateStruct":658,"completionDateStruct":660,"leadSponsor":662,"locationsCount":51},"100597904","evaluation-study-of-medical-social-collaboration-model-for-middle-aged-and-older-adults-with-depressive-symptoms-100597904","NCT07064551","Evaluation Study of Medical-Social Collaboration Model for Middle-aged and Older Adults With Depressive Symptoms","Inclusion Criteria:\n\n* Currently awaiting psychiatric services provided by the Hospital Authority\n* Have depressive symptoms of at least mild severity\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* A known history of autism spectrum disorder, intellectual disability, schizophrenia-spectrum disorder, bipolar disorder, Parkinson's disease, or dementia\n* Imminent suicidal risk (temporary exclusion)\n* Communication difficulties that preclude participation",{"count":644,"type":22},192,[25],"The goal of this clinical trial is to learn if a medical-social collaboration model works to reduce depressive symptoms in middle-aged and older adults with depressive symptoms who are waiting for their first psychiatric appointment. Secondary outcomes of the study include reduced anxiety symptoms, reduced loneliness, reduced rumination, reduced self-criticism, improved self-reassurance, improved resilience, improved self-efficacy, improved health-related quality of life, as well as improved quality-adjusted life years, and reduced healthcare service utilisation.\n\nResearchers will compare a medical-social collaboration model to a self-management booklet.\n\nParticipants will:\n\n* Receive CBT-based stepped-care interventions through the medical-social collaboration model or a self-management booklet.\n* Complete a survey about their mental health and service use every three months until their first psychiatric appointment.",[648],"Depression",[650,651,652,653,654],"Depressive symptoms","Mental health","Medical-social collaboration","Integrated health and social care","Stepped-care intervention","2026-07-19",{"date":657,"type":43},"2026-07-21",{"date":659,"type":43},"2025-06-20",{"date":661,"type":22},"2027-06",{"name":49,"class":50},{"id":664,"slug":665,"hasResults":12,"nctId":666,"briefTitle":667,"officialTitle":668,"acronym":4,"eligibilityCriteria":669,"healthyVolunteers":349,"sex":18,"minAge":670,"maxAge":671,"enrollmentInfo":672,"targetDuration":4,"studyType":23,"phases":674,"briefSummary":675,"conditions":676,"keywords":681,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":689,"lastUpdatePostDateStruct":690,"startDateStruct":692,"completionDateStruct":694,"leadSponsor":695,"locationsCount":51},"100648213","effectiveness-of-a-self-health-assessment-mobile-application-in-young-to-midlife-adults-in-hong-kong-100648213","NCT07720245","Effectiveness of a Self-health Assessment Mobile Application in Young-to-midlife Adults in Hong Kong","Effectiveness of Self-health Assessment Mobile Application to Promote Health Awareness, Empower Patients and Improve Linkage-to-care Amongst Young-to-midlife Adults in Hong Kong: a Randomised Controlled Trial","Inclusion Criteria:\n\n* Hong Kong residents self-reported age of 25-65 years;\n* Possesses a smartphone capable of running mobile apps (e.g. Android or iPhone) and;\n* Able to read either English or Chinese.\n\nExclusion Criteria:\n\n* Individuals having any symptoms or feeling unwell in anyways as detailed in the Disclaimer at the launch of the app; or\n* Individuals reporting a current diagnosis of cardiovascular disease, lung cancer, hepatitis B, colorectal cancer, diabetes, sexually transmitted diseases, depression, anxiety and mild cognitive impairment and memory loss.","25 Years","65 Years",{"count":673,"type":22},574,[25],"This project aims to compare the effectiveness of Wellnuts, an evidence-based, algorithm-driven self-health assessment mobile application, in empowering asymptomatic young-to-midlife adults in Hong Kong, promoting health awareness, and improving health-seeking behaviour and linkage-to-care, compared with conventional web-based health resources. Participants will be randomly allocated to the mobile health intervention group (Wellnuts app with self-health assessment and health information) and the conventional web-based resources control group (health information from Centre for Health Protection website). Hopefully, population health will be improved with the general health promotion impact from the app.",[677,678,679,304,680],"Diabetes Risk","CVD Risk","Colorectal Cancer","HBV",[682,683,684,685,686,687,688,498],"Self-health assessment","Mobile application","Health awareness","Health empowerment","Linkage-to-care","Chronic disease","Randomised control trial","2026-07-17",{"date":691,"type":43},"2026-07-22",{"date":693,"type":43},"2024-06-01",{"date":154,"type":22},{"name":49,"class":50},""]